News | August 15, 2022
Arbitrator rules in favor of Daiichi Sankyo in dispute with Seagen
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
The money will be donated to the United Nations Children’s Fund (UNICEF)
DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by the company
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
Subscribe To Our Newsletter & Stay Updated
